RenovoRx Inc
renovorx.comWhat Do They Do?
Sells a drug-delivery catheter to cancer centers and develops cancer therapies designed to deliver chemotherapy near tumors.
10-K for FY2025, filed Mar 30, 2026We are a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, U.S. Food and…View ↗
Our patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, enabled by RenovoCath, is designed for targeted therapeutic delivery…View ↗
We are actively commercializing the TAMP therapy platform and RenovoCath as a stand-alone device within its FDA cleared fields of use. We…View ↗
We are also evaluating our novel drug-device combination oncology product candidate (IA delivery of the FDA-approved chemotherapy…View ↗
How Do They Make Money?
End users buy RenovoCath directly, usually through purchase orders; payment is generally due 30–90 days after shipment.
10-K for FY2025, filed Mar 30, 2026The Company derives revenue through sales of its FDA-cleared catheter drug-delivery device, RenovoCath, directly to end users, which began…View ↗
$1.1M
-
10-K for FY2025, filed Mar 30, 2026
$1.1M ↗
Who Are Their Customers?
RenovoRx sells directly to end users, mainly U.S. cancer centers, using customer purchase orders.
10-K for FY2025, filed Mar 30, 2026
10-K for FY2025, filed Mar 30, 2026
For the year ended Decemer 31, 2025, three customers each accounted for 10% or more of the total revenues. Customer A, Customer B, and…View ↗
Do Revenues Turn Into Profits?
No. It lost $11.2M in FY2025.
10-K for FY2025, filed Mar 30, 2026
−$12.5MView ↗
10-K for FY2025, filed Mar 30, 2026
−$11.2MView ↗
10-K for FY2025, filed Mar 30, 2026
−$11MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$2.9MView ↗
- ▲ +1% (Loss)
- vs −$2.9M in Q2 FY2025
-
Aug 20, 2026
Regained Nasdaq minimum-bid-price compliance
Nasdaq confirmed the stock met the $1.00 minimum bid-price requirement for ten consecutive business days, closing the matter.
Sources
8-K, filed Aug 20, 2026
On August 20, 2026, the Company received written confirmation from Nasdaq notifying the Company that for the ten consecutive business days…View ↗
-
Jul 2, 2026
Nasdaq extended the deadline to meet the minimum bid-price rule
Nasdaq gave RenovoRx another 180 calendar days, through December 28, 2026, to regain compliance; otherwise its stock could be delisted.
Sources
8-K, filed Jul 2, 2026
On July 1, 2026, the Company received a notification letter from Nasdaq informing the Company that, while the Company has not yet regained…View ↗
Standalone device sales
The older report focuses on RenovoGem as a clinical-stage drug-device candidate; the latest report also describes commercializing RenovoCath as a standalone device, alongside continued clinical development of IAG.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 30, 2026RenovoRx is a clinical-stage biopharmaceutical company with a vision to disrupt the current paradigm of cancer treatment. Our mission is to…View ↗
We are actively commercializing the TAMP therapy platform and RenovoCath as a stand-alone device within its FDA cleared fields of use. We…View ↗
We are also evaluating our novel drug-device combination oncology product candidate (IA delivery of the FDA-approved chemotherapy…View ↗
Until 2025, we focused our efforts primarily on progressing IAG through our ongoing Phase III TIGeR-PaC study for LAPC. The clinical…View ↗
Who Do They Compete With?
Competes with Novocure, Revolution Medicines, FibroGen, and TriSalus Life Sciences
10-K for FY2025, filed Mar 30, 2026In February 2026, Novocure’s Optune Pax concomitant with gemcitabine and nab-paclitaxel was the first treatment to be FDA approved in…View ↗
Loading...
